{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:46:09Z","timestamp":1788975969652,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"The National Research Foundation of Korea","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mesenchymal stem cells (MSCs) loaded with oncolytic viruses are presently being investigated as a new modality of advanced\/metastatic tumors treatment and enhancement of virotherapy. MSCs can, however, either promote or suppress tumor growth. To address the critical question of how MSCs loaded with oncolytic viruses affect virotherapy outcomes and tumor growth patterns in a tumor microenvironment, we developed and analyzed an integrated mathematical-experimental model. We used the model to describe both the growth dynamics in our experiments of firefly luciferase-expressing Hep3B tumor xenografts and the effects of the immune response during the MSCs-based virotherapy. We further employed it to explore the conceptual clinical feasibility, particularly, in evaluating the relative significance of potential immune promotive\/suppressive mechanisms induced by MSCs loaded with oncolytic viruses. We were able to delineate conditions which may significantly contribute to the success or failure of MSC-based virotherapy as well as generate new hypotheses. In fact, one of the most impactful outcomes shown by this investigation, not inferred from the experiments alone, was the initially counter-intuitive fact that using tumor-promoting MSCs as carriers is not only helpful but necessary in achieving tumor control. Considering the fact that it is still currently a controversial debate whether MSCs exert a pro- or anti-tumor action, mathematical models such as this one help to quantitatively predict the consequences of using MSCs for delivering virotherapeutic agents <jats:italic>in vivo<\/jats:italic>. Taken together, our results show that MSC-mediated systemic delivery of oncolytic viruses is a promising strategy for achieving synergistic anti-tumor efficacy with improved safety profiles.<\/jats:p>","DOI":"10.1038\/s41598-019-57240-x","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T11:03:28Z","timestamp":1579172608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Khaphetsi Joseph","family":"Mahasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"de Pillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-1792","authenticated-orcid":false,"given":"Rachid","family":"Ouifki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Eladdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Rum","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"57240_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/v8010009","volume":"8","author":"A Marchini","year":"2016","unstructured":"Marchini, A., Scott, E. & Rommelaere, J. Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade. Viruses 8, 9 (2016).","journal-title":"Viruses"},{"key":"57240_CR2","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.3390\/v7122921","volume":"7","author":"J Kim","year":"2015","unstructured":"Kim, J., Hall, R., Lesniak, M. & Ahmed, A. Stem cell-based cell carrier for targeted oncolytic virotherapy: Translational opportunity and Open questions. Viruses 7, 6200\u20136217 (2015).","journal-title":"Viruses"},{"key":"57240_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/OV.S36623","volume":"2","author":"D Roy","year":"2013","unstructured":"Roy, D. & Bell, J. Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virotherapy 2, 47\u201356, https:\/\/doi.org\/10.2147\/OV.S36623 (2013).","journal-title":"Oncolytic Virotherapy"},{"key":"57240_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/bjc.2015.481","volume":"114","author":"L Seymour","year":"2016","unstructured":"Seymour, L. & Fisher, K. Oncolytic viruses: finally delivering. Br. journal cancer 114, 357\u2013361, https:\/\/doi.org\/10.1038\/bjc.2015.481 (2016).","journal-title":"Br. journal cancer"},{"key":"57240_CR5","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1126\/science.1121411","volume":"311","author":"S Thorne","year":"2006","unstructured":"Thorne, S., Negrin, R. & Contag, C. Synergistic antitumor effects of immune cell-viral biotherapy. Sci. 311, 1780\u20131784 (2006).","journal-title":"Sci."},{"key":"57240_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2012.257","volume":"21","author":"P Sampath","year":"2013","unstructured":"Sampath, P. et al. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol. Ther. 21, 620\u2013628 (2013).","journal-title":"Mol. Ther."},{"key":"57240_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/gt.2009.29","volume":"16","author":"E Ilett","year":"2009","unstructured":"Ilett, E. et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene therapy 16, 689\u2013699 (2009).","journal-title":"Gene therapy"},{"key":"57240_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41419-018-0366-7","volume":"9","author":"C Zong","year":"2018","unstructured":"Zong, C. et al. The distinct roles of mesenchymal stem cells in the initial and progressive stage of hepatocarcinoma. Cell death & disease 9, 345 (2018).","journal-title":"Cell death & disease"},{"key":"57240_CR9","doi-asserted-by":"publisher","first-page":"30015","DOI":"10.3390\/ijms161226215","volume":"16","author":"K Rhee","year":"2015","unstructured":"Rhee, K., Lee, J. & Eom, Y. Mesenchymal stem cell-mediated effects of tumor support or suppression. Int. journal molecular sciences 16, 30015\u201330033 (2015).","journal-title":"Int. journal molecular sciences"},{"key":"57240_CR10","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/onc.2012.458","volume":"32","author":"W Huang","year":"2013","unstructured":"Huang, W. et al. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 32, 4343 (2013).","journal-title":"Oncogene"},{"key":"57240_CR11","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/mt.2010.131","volume":"18","author":"A Ahmed","year":"2010","unstructured":"Ahmed, A. et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol. Ther. 18, 1846\u20131856 (2010).","journal-title":"Mol. Ther."},{"key":"57240_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1634\/stemcells.2007-0758","volume":"26","author":"A Sonabend","year":"2008","unstructured":"Sonabend, A. et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26, 831\u2013841 (2008).","journal-title":"Stem Cells"},{"key":"57240_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.neo.2017.02.010","volume":"19","author":"H Takigawa","year":"2017","unstructured":"Takigawa, H. et al. Mesenchymal stem cells induce epithelial to mesenchymal transition in colon cancer cells through direct cell-to-cell contact. Neoplasia 19, 429\u2013438 (2017).","journal-title":"Neoplasia"},{"key":"57240_CR14","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.bbadis.2017.02.023","volume":"1863","author":"N Wang","year":"2017","unstructured":"Wang, N. et al. Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis. Biochimica et Biophys. Acta (BBA)-Molecular Basis Dis. 1863, 2085\u20132092 (2017).","journal-title":"Biochimica et Biophys. Acta (BBA)-Molecular Basis Dis."},{"key":"57240_CR15","doi-asserted-by":"publisher","first-page":"73296","DOI":"10.18632\/oncotarget.20265","volume":"8","author":"B Hill","year":"2017","unstructured":"Hill, B., Pelagalli, A., Passaro, N. & Zannetti, A. Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype. Oncotarget 8, 73296 (2017).","journal-title":"Oncotarget"},{"key":"57240_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2013.07.010","volume":"59","author":"H Ong","year":"2013","unstructured":"Ong, H. et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J. hepatology 59, 999\u20131006 (2013).","journal-title":"J. hepatology"},{"key":"57240_CR17","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1158\/1078-0432.CCR-09-1292","volume":"15","author":"E Mader","year":"2009","unstructured":"Mader, E. et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res. 15, 7246\u20137255 (2009).","journal-title":"Clin. Cancer Res."},{"key":"57240_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1158\/1535-7163.MCT-05-0334","volume":"5","author":"S Komarova","year":"2006","unstructured":"Komarova, S., Kawakami, Y., Stoff-Khalili, M., Curiel, D. & Pereboeva, L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. cancer therapeutics 5, 755\u2013766 (2006).","journal-title":"Mol. cancer therapeutics"},{"key":"57240_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/stem.559","volume":"29","author":"A Klopp","year":"2011","unstructured":"Klopp, A., Gupta, A., Spaeth, E., Andreeff, M. & Marini, F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem cells 29, 11\u201319 (2011).","journal-title":"Stem cells"},{"key":"57240_CR20","first-page":"4197","volume":"113","author":"K Otsu","year":"2009","unstructured":"Otsu, K. et al. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Exp. molecular pathology 113, 4197\u20134205 (2009).","journal-title":"Exp. molecular pathology"},{"key":"57240_CR21","doi-asserted-by":"publisher","first-page":"e6278","DOI":"10.1371\/journal.pone.0006278","volume":"4","author":"B Cousin","year":"2009","unstructured":"Cousin, B. et al. Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS One 4, e6278 (2009).","journal-title":"PLoS One"},{"key":"57240_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.yexmp.2003.06.001","volume":"75","author":"L Ohlsson","year":"2003","unstructured":"Ohlsson, L., Varas, L., Kjellman, C., Edvardsen, K. & Lindvall, M. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp. molecular pathology 75, 248\u2013255 (2003).","journal-title":"Exp. molecular pathology"},{"key":"57240_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2008.04.032","volume":"269","author":"L Qiao","year":"2008","unstructured":"Qiao, L., Xu, Z., Zhao, T., Ye, L. & Zhang, X. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of wnt signalling. Cancer letters 269, 67\u201377 (2008).","journal-title":"Cancer letters"},{"key":"57240_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2015.11.036","volume":"371","author":"G Melen","year":"2016","unstructured":"Melen, G. et al. Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer letters 371, 161\u2013170 (2016).","journal-title":"Cancer letters"},{"key":"57240_CR25","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.2147\/OTT.S63049","volume":"9","author":"L Aurelian","year":"2016","unstructured":"Aurelian, L. Oncolytic viruses as immunotherapy: progress and remaining challenges. OncoTargets therapy 9, 2627\u20132637, https:\/\/doi.org\/10.2147\/OTT.S63049 (2016).","journal-title":"OncoTargets therapy"},{"key":"57240_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/OTT.S63049","volume":"4","author":"M Ram\u00dfrez","year":"2016","unstructured":"Ram$${\\acute{\\beta}}$$rez, M., Garc$${\\acute{\\beta}}$$a-Castro, J., Melen, G., Gonzlez-Murillo, \u00c1. & Franco-Luz\u00f3n, L. Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology. Oncolytic Virotherapy 4, 149, https:\/\/doi.org\/10.2147\/OTT.S63049 (2016).","journal-title":"Oncolytic Virotherapy"},{"key":"57240_CR27","doi-asserted-by":"publisher","first-page":"11208","DOI":"10.1063\/1.3699060","volume":"2","author":"A van de Ven","year":"2012","unstructured":"van de Ven, A. et al. Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP advances 2, 11208 (2012).","journal-title":"AIP advances"},{"key":"57240_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nnano.2010.58","volume":"5","author":"B Kim","year":"2010","unstructured":"Kim, B. et al. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat. nanotechnology 5, 465\u2013472 (2010).","journal-title":"Nat. nanotechnology"},{"key":"57240_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3109\/02656731003623590","volume":"26","author":"A Gasselhuber","year":"2010","unstructured":"Gasselhuber, A. et al. Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. Int. J. Hyperth. 26, 499\u2013513 (2010).","journal-title":"Int. J. Hyperth."},{"key":"57240_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtbi.2003.09.004","volume":"226","author":"M Owen","year":"2004","unstructured":"Owen, M., Byrne, H. & Lewis, C. Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. J. Theor. Biol. 226, 377\u2013391 (2004).","journal-title":"J. Theor. Biol."},{"key":"57240_CR31","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s11538-006-9189-2","volume":"69","author":"S Webb","year":"2007","unstructured":"Webb, S., Owen, M., Byrne, H., Murdoch, C. & Lewis, C. Macrophage-based anti-cancer therapy: modelling different modes of tumour targeting. Bull. Math. Biol. 69, 1747\u20131776 (2007).","journal-title":"Bull. Math. Biol."},{"issue":"17","key":"57240_CR32","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1158\/0008-5472.CAN-18-3900","volume":"79","author":"A-Rum Yoon","year":"2019","unstructured":"Yoon, A. et al. Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer research canres\u20133900, https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3900 (2019).","journal-title":"Cancer Research"},{"key":"57240_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","volume":"23","author":"X Li","year":"2017","unstructured":"Li, X. et al. The efficacy of oncolytic adenovirus is mediated by T cell responses against virus and tumor in Syrian hamster model. Clin. Cancer Res. 23, 239\u2013249 (2017).","journal-title":"Clin. Cancer Res."},{"key":"57240_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omto.2019.03.001","volume":"14","author":"T Pearl","year":"2019","unstructured":"Pearl, T., Markert, J., Cassady, K. & Ghonime, M. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol. therapy oncolytics 14, 14, https:\/\/doi.org\/10.1016\/j.omto.2019.03.001 (2019).","journal-title":"Mol. therapy oncolytics"},{"key":"57240_CR35","doi-asserted-by":"publisher","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","volume":"6","author":"K Perica","year":"2015","unstructured":"Perica, K., Varela, J., Oelke, M. & Schneck, J. Adoptive t cell immunotherapy for cancer. Rambam Maimonides medical journal 6, e0004 (2015).","journal-title":"Rambam Maimonides medical journal"},{"key":"57240_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3934\/mbe.2015.12.841","volume":"12","author":"P Kim","year":"2015","unstructured":"Kim, P., Crivelli, J., Choi, I., Yun, C. & Wares, J. Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics. Math. biosciences engineering 12, 841\u2013858 (2015).","journal-title":"Math. biosciences engineering"},{"key":"57240_CR37","doi-asserted-by":"publisher","first-page":"e0184347","DOI":"10.1371\/journal.pone.0184347","volume":"12","author":"K Mahasa","year":"2017","unstructured":"Mahasa, K., Eladdadi, A., de Pillis, L. & Ouifki, R. Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. PLoS ONE 12, e0184347 (2017).","journal-title":"PLoS ONE"},{"key":"57240_CR38","doi-asserted-by":"crossref","unstructured":"de Pillis, L. & Radunskaya, A. A mathematical model of immune response to tumor invasion. In Computational Fluid and Solid Mechanics, 1661\u20131668 (ed. Bathe, K. J. (Elsevier Science Ltd), 2003).","DOI":"10.1016\/B978-008044046-0.50404-8"},{"key":"57240_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cytogfr.2010.02.007","volume":"21","author":"N Silva","year":"2010","unstructured":"Silva, N., Atkins, H., Kirn, D., Bell, J. & Breitbach, C. Double trouble for tumours: Exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses. Cytokine & growth factor reviews 21, 135\u2013141 (2010).","journal-title":"Cytokine & growth factor reviews"},{"key":"57240_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11538-015-0074-8","volume":"77","author":"K Jacobsen","year":"2015","unstructured":"Jacobsen, K., Russell, L., Kaur, B. & Friedman, A. Effects of CCN1 and macrophage content on glioma virotherapy: A mathematical model. Bull. mathematical biology 77, 1\u201329 (2015).","journal-title":"Bull. mathematical biology"},{"key":"57240_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-11-20","volume":"11","author":"E Mader","year":"2013","unstructured":"Mader, E. et al. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J. translational medicine 11, 1\u201314 (2013).","journal-title":"J. translational medicine"},{"key":"57240_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/cgt.2010.4","volume":"17","author":"J Garc\u00b4\u00dfa-Castro","year":"2010","unstructured":"Garc$${\\acute{\\beta}}$$a-Castro, J. et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer gene therapy 17, 476\u2013483 (2010).","journal-title":"Cancer gene therapy"},{"key":"57240_CR43","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/ijc.29442","volume":"137","author":"K Hammer","year":"2015","unstructured":"Hammer, K. et al. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int. J. Cancer 137, 978\u2013990 (2015).","journal-title":"Int. J. Cancer"},{"key":"57240_CR44","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1093\/carcin\/bgt210","volume":"34","author":"P Hernanda","year":"2013","unstructured":"Hernanda, P. et al. Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Carcinog. 34, 2330\u20132340 (2013).","journal-title":"Carcinog."},{"key":"57240_CR45","doi-asserted-by":"publisher","first-page":"9474","DOI":"10.1038\/s41598-018-27718-1","volume":"8","author":"R Walker","year":"2018","unstructured":"Walker, R. et al. Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Sci. reports 8, 9474 (2018).","journal-title":"Sci. reports"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-57240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-57240-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-57240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:32:19Z","timestamp":1670304739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-57240-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["57240"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-57240-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,16]]},"assertion":[{"value":"26 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"425"}}